Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Tumor Biology
Published in: Tumor Biology 5/2015

01-05-2015 | Review

Role of pancreatic stellate cells and periostin in pancreatic cancer progression

Authors: Yang Liu, Lianfang Du

Published in: Tumor Biology | Issue 5/2015

Login to get access

Abstract

Pancreatic ductal adenocarcinoma (PDAC) is an aggressive and one of the five most lethal malignancies characterized by prominent desmoplastic reaction. Accumulating evidences indicate that tumor desmoplasia plays a pivotal role in PDAC progression, and it has been largely ignored until recent times. It has now been unequivocally shown that pancreatic stellate cells (PSCs) are the principal effector cells responsible for stroma production. Periostin, also known as osteoblast-specific factor 2, is a secretory protein and originally identified as an osteoblast-specific factor that expressed in periosteum. Periostin is exclusively produced by activated PSCs, and periostin overexpression presents in various malignant tumors and closely relates with disease progression. In addition, periostin has been suggested to stimulate pancreatic cancer cells proliferation and enhance their resistance to serum starvation and hypoxia. Therefore, the interplay between cancer cells and stromal cells plays a vital role in PDAC development. However, the function of periostin in pancreatic cancer development is controversial. This review summarizes existing knowledge about the role of PSCs in cancer stroma production, the interaction between PSCs and pancreatic cancer cells, tumor angiogenesis, and hypoxic microenvironment, with particular focus on the expression and function as well as signaling pathways of periostin in PDAC cells and PSCs.
Literature
1.
2.
3.
Erkan M. The role of stroma in pancreatic cancer: diagnostic and therapeutic implications. Nat Rev Gastroenterol Hepatol. 2012;9:454–67.CrossRefPubMed
4.
Bachem MG. Pancreatic carcinoma cells induce fibrosis by stimulating proliferation and matrix synthesis of stellate cells. Gastroenterology. 2005;128:907–21.CrossRefPubMed
5.
Erkan M. The activated stroma index is a novel and independent prognostic marker in pancreatic ductal adenocarcinoma. Clin Gastroenterol Hepatol. 2008;6:1155–61.CrossRefPubMed
6.
7.
Duner S. Pancreatic cancer: the role of pancreatic stellate cells in tumor progression. Pancreatology. 2010;10:673–81.CrossRefPubMed
8.
Haqq J. Pancreatic stellate cells and pancreas cancer: current perspectives and future strategies. Eur J Cancer. 2014;50:2570–82.CrossRefPubMed
9.
Haage A, Schneider IC. Cellular contractility and extracellular matrix stiffness regulate matrix metalloproteinase activity in pancreatic cancer cells. FASEB J. 2014;28:3589–99.CrossRefPubMed
10.
Takeshita S. Osteoblast-specific factor 2: cloning of a putative bone adhesion protein with homology with the insect protein fasciclin I. Biochem J. 1993;294(Pt 1):271–8.CrossRefPubMedPubMedCentral
11.
12.
Ben QW. Periostin, a matrix specific protein, is associated with proliferation and invasion of pancreatic cancer. Oncol Rep. 2011;25:709–16.PubMed
13.
Erkan M. Periostin creates a tumor-supportive microenvironment in the pancreas by sustaining fibrogenic stellate cell activity. Gastroenterology. 2007;132:1447–64.CrossRefPubMed
14.
15.
Morra L. Characterization of periostin isoform pattern in non-small cell lung cancer. Lung Cancer. 2012;76:183–90.CrossRefPubMed
16.
Sasaki H. Expression of the periostin mRNA level in neuroblastoma. J Pediatr Surg. 2002;37:1293–7.CrossRefPubMed
17.
Baril P. Periostin promotes invasiveness and resistance of pancreatic cancer cells to hypoxia-induced cell death: role of the beta4 integrin and the PI3k pathway. Oncogene. 2007;26:2082–94.CrossRefPubMed
18.
Merle B, Garnero P. The multiple facets of periostin in bone metabolism. Osteoporos Int. 2012;23:1199–212.CrossRefPubMed
19.
Conway SJ. The inter-relationship of periostin, TGF beta, and BMP in heart valve development and valvular heart diseases. Sci World J. 2011;11:1509–24.CrossRef
20.
Romanos GE. PERIOSTIN: role in formation and maintenance of dental tissues. J Cell Physiol. 2014;229:1–5.PubMed
21.
Rios H. periostin null mice exhibit dwarfism, incisor enamel defects, and an early-onset periodontal disease-like phenotype. Mol Cell Biol. 2005;25:11131–44.CrossRefPubMedPubMedCentral
22.
23.
Lie-Venema H. Periostin expression by epicardium-derived cells is involved in the development of the atrioventricular valves and fibrous heart skeleton. Differentiation. 2008;76:809–19.CrossRefPubMed
24.
Zhao S. Periostin expression is upregulated and associated with myocardial fibrosis in human failing hearts. J Cardiol. 2014;63:373–8.CrossRefPubMed
25.
Stansfield WE. Periostin is a novel factor in cardiac remodeling after experimental and clinical unloading of the failing heart. Ann Thorac Surg. 2009;88:1916–21.CrossRefPubMedPubMedCentral
26.
Li J. [Roles of periostin in proliferation and migration of vascular smooth muscle cells and the effect of atorvastatin on them]. Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2012;37:689–94.PubMed
27.
Rani S. Induction of periostin-like factor and periostin in forearm muscle, tendon, and nerve in an animal model of work-related musculoskeletal disorder. J Histochem Cytochem. 2009;57:1061–73.CrossRefPubMedPubMedCentral
28.
Goetsch SC. Transcriptional profiling and regulation of the extracellular matrix during muscle regeneration. Physiol Genomics. 2003;14:261–71.CrossRefPubMed
29.
Rousseau JC. Serum periostin is associated with fracture risk in postmenopausal women: a 7-year prospective analysis of the OFELY study. J Clin Endocrinol Metab. 2014;99:2533–9.CrossRefPubMed
30.
Nuzzo PV. Periostin: a novel prognostic and therapeutic target for genitourinary cancer? Clin Genitourin Cancer. 2014;12:301–11.CrossRefPubMed
31.
Gillan L. Periostin secreted by epithelial ovarian carcinoma is a ligand for alpha (V) beta (3) and alpha (V) beta (5) integrins and promotes cell motility. Cancer Res. 2002;62:5358–64.PubMed
32.
Kim CJ. Role of alternative splicing of periostin in human bladder carcinogenesis. Int J Oncol. 2008;32:161–9.PubMed
33.
34.
Apte MV. Desmoplastic reaction in pancreatic cancer: role of pancreatic stellate cells. Pancreas. 2004;29:179–87.CrossRefPubMed
35.
Heinemann V. Tumour-stroma interactions in pancreatic ductal adenocarcinoma: rationale and current evidence for new therapeutic strategies. Cancer Treat Rev. 2014;40:118–28.CrossRefPubMed
36.
Yoshitomi H. Specific expression of endoglin (CD105) in endothelial cells of intratumoral blood and lymphatic vessels in pancreatic cancer. Pancreas. 2008;37:275–81.CrossRefPubMed
37.
Froeling FE. Organotypic culture model of pancreatic cancer demonstrates that stromal cells modulate E-cadherin, beta-catenin, and Ezrin expression in tumor cells. Am J Pathol. 2009;175:636–48.CrossRefPubMedPubMedCentral
38.
Vonlaufen A. Pancreatic stellate cells: partners in crime with pancreatic cancer cells. Cancer Res. 2008;68:2085–93.CrossRefPubMed
39.
40.
41.
Gemcitabine plus bevacizumab no better than gemcitabine alone in clinical study of 600 patients with pancreatic cancer. Cancer Biol Ther. 2007;6:137.
42.
Reiser-Erkan C. Hypoxia-inducible proto-oncogene Pim-1 is a prognostic marker in pancreatic ductal adenocarcinoma. Cancer Biol Ther. 2008;7:1352–9.CrossRefPubMed
43.
Couvelard A. Expression of hypoxia-inducible factors is correlated with the presence of a fibrotic focus and angiogenesis in pancreatic ductal adenocarcinomas. Histopathology. 2005;46:668–76.CrossRefPubMed
44.
Erkan M. StellaTUM: current consensus and discussion on pancreatic stellate cell research. Gut. 2012;61:172–8.CrossRefPubMed
45.
Kanno A. Periostin, secreted from stromal cells, has biphasic effect on cell migration and correlates with the epithelial to mesenchymal transition of human pancreatic cancer cells. Int J Cancer. 2008;122:2707–18.CrossRefPubMed
46.
Conway SJ. The role of periostin in tissue remodeling across health and disease. Cell Mol Life Sci. 2014;71:1279–88.CrossRefPubMed
Metadata
Title
Role of pancreatic stellate cells and periostin in pancreatic cancer progression
Authors
Yang Liu
Lianfang Du
Publication date
01-05-2015
Publisher
Springer Netherlands
Published in
Tumor Biology / Issue 5/2015
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-015-3386-2

Other articles of this Issue 5/2015

Tumor Biology 5/2015 Go to the issue

Editorial

Note of clarification of data in the paper titled X-ray repair cross-complementing group 1 codon 399 polymorphism and lung cancer risk: an updated meta-analysis

Research Article

Fenofibrate induces G0/G1 phase arrest by modulating the PPARα/FoxO1/p27kip pathway in human glioblastoma cells

Research Article

RBPJ inhibition impairs the growth of lung cancer

Research Article

Indole-3-carbinol suppresses NF-κB activity and stimulates the p53 pathway in pre-B acute lymphoblastic leukemia cells

Research Article

Association of SOX4 regulated by tumor suppressor miR-30a with poor prognosis in low-grade chondrosarcoma

Research Article

MicroPET imaging of tumor angiogenesis and monitoring on antiangiogenic therapy with an 18F labeled RGD-based probe in SKOV-3 xenograft-bearing mice
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits